<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036980</url>
  </required_header>
  <id_info>
    <org_study_id>200-302</org_study_id>
    <nct_id>NCT05036980</nct_id>
  </id_info>
  <brief_title>Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium Crocetinate in Healthy Volunteers Exercising at Altitude</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium Crocetinate in Healthy Volunteers Exercising at Altitude</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diffusion Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diffusion Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, crossover study of Trans Sodium Crocetinate (TSC)&#xD;
      in healthy volunteers, age 18-40 (inclusive), exercising at altitude. The primary objective&#xD;
      is to determine the effect of (TSC) on partial pressure of oxygen (PaO2) and maximal oxygen&#xD;
      consumption (VO2 max); the secondary objective is to assess the effect of TSC on oxygen&#xD;
      saturation (SpO2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sequence matched median PaO2 per dose cohort comparing TSC vs PBO</measure>
    <time_frame>Up to 10 Â± 1 minutes after final VO2 max</time_frame>
    <description>Comparison of partial pressure of oxygen (PaO2) at altitude between control and experimental exposures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sequence matched median VO2 per dose cohort comparing TSC vs PBO</measure>
    <time_frame>Up to 33 minutes (achievement of peak wattage)</time_frame>
    <description>Comparison of maximal oxygen consumption (VO2 max) at altitude between control and experimental exposures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of TSC on Median Oxygen Saturation</measure>
    <time_frame>Up to 33 minutes (achievement of peak wattage)</time_frame>
    <description>Comparison of oxygen saturation (SpO2) between the control and experimental exposures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of TSC on Median Serum Lactate Concentration</measure>
    <time_frame>Up to 33 minutes (achievement of peak wattage)</time_frame>
    <description>Comparison of lactate between the control and experimental exposures</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy Volunteers With Induced Hypoxia</condition>
  <arm_group>
    <arm_group_label>0.5 mg/kg Trans Sodium Crocetinate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single IV bolus dose of 0.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5 mg/kg Trans Sodium Crocetinate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single IV bolus dose of 1.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5 mg/kg Trans Sodium Crocetinate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single IV bolus dose of 2.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trans Sodium Crocetinate</intervention_name>
    <description>Single IV bolus</description>
    <arm_group_label>0.5 mg/kg Trans Sodium Crocetinate</arm_group_label>
    <arm_group_label>1.5 mg/kg Trans Sodium Crocetinate</arm_group_label>
    <arm_group_label>2.5 mg/kg Trans Sodium Crocetinate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males and females ages 18-40&#xD;
&#xD;
          2. Non-smoking&#xD;
&#xD;
          3. Able to provide informed consent and agree to adhere to all study visits and&#xD;
             requirements.&#xD;
&#xD;
          4. Females of childbearing potential must have a negative blood pregnancy test at&#xD;
             screening and agree to use one of the accepted contraceptive regimens, or a double&#xD;
             method of birth control during the study and at least 30 days after the last dose of&#xD;
             study drug.&#xD;
&#xD;
          5. Males who engage in sexual activity that has the risk of pregnancy must agree to use a&#xD;
             double barrier method and agree not to donate sperm during the study and for at least&#xD;
             90 days after the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy to study medication&#xD;
&#xD;
          2. Pregnant or breast feeding&#xD;
&#xD;
          3. Received investigational medicine (IMP) within past 30 days&#xD;
&#xD;
          4. VO2 max &lt; 35 mL/kg/min (male), &lt; 30 mL/kg/min (female) at screening&#xD;
&#xD;
          5. Abnormal pulmonary function testing at screening&#xD;
&#xD;
          6. Surgery or hospitalization in past 3 months determined by the PI to be clinically&#xD;
             relevant&#xD;
&#xD;
          7. History of ongoing alcohol or substance abuse&#xD;
&#xD;
          8. Known cardiovascular disease, including treated or untreated hypertension&#xD;
&#xD;
          9. Respiratory disease and/or any other significant medical condition, including&#xD;
             psychiatric disorders&#xD;
&#xD;
         10. Clinically significant abnormality on ECG per PI discretion&#xD;
&#xD;
         11. Blood donation (excluding plasma donation) of approximately 500 mL within 56 days&#xD;
             prior to screening&#xD;
&#xD;
         12. Plasma donation within 7 days prior to screening&#xD;
&#xD;
         13. Treatment with an investigational drug within 30 days or 5 times the half-life&#xD;
             (whichever is longer) prior to screening&#xD;
&#xD;
         14. History of smoking&#xD;
&#xD;
         15. Urine screen positive for drugs or positive breathalyzer for alcohol (at screening and&#xD;
             Treatment Visit Day 1)&#xD;
&#xD;
         16. History of seizures&#xD;
&#xD;
         17. Previous pneumothorax or pneumomediastinum&#xD;
&#xD;
         18. Hypo/Hyperglycemia&#xD;
&#xD;
         19. Diabetes&#xD;
&#xD;
         20. Regularly taking medications which may alter heart rate, blood pressure or cardiac&#xD;
             output&#xD;
&#xD;
         21. Previous history of middle ear equalization problems at discretion of PI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kelly Arscott</last_name>
    <phone>(434) 220-0718</phone>
    <email>karscott@diffusionpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chris Galloway, MD</last_name>
    <phone>(434) 220-0718</phone>
    <email>cgalloway@diffusionpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>22710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Derrick, MD</last_name>
      <email>bruce.derrick@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Bruce Derrick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trans-sodium crocetinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

